Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy Vaccines
Data on cancer gene therapy vaccines reported by S. Dharmapuri and co-researchers
April 29th, 2009
Research findings, 'An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models,' are discussed in a new report. According to a study from Pomezia, Italy, "In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target antigen in a variety of species. To further enhance the efficacy of DNA-EP, we have evaluated the toll-like receptor7 (TLR7) agonist-2, 9, substituted 8-hydroxyadenosine derivative or SM360320--as an adjuvant to vaccines against HER2/neu and CEA in BALB-neuT and CEA transgenic mice (CEA.Tg),...
Source: Vaccine Weekly (2009-04-29)
|
